2023年,第59届美国临床肿瘤学会(ASCO)年会将于美国芝加哥当地时间6月2日至6日举行。目前ASCO官网已公布了本次会议的日程和摘要题目。本期【肿瘤资讯】整理了2023 ASCO年会口头报告(Oral Abstract Session)专场的泌尿肿瘤领域的精彩重磅研究,与读者分享。
前列腺癌、睾丸癌和阴茎癌
6月4日 北京时间 21:00-00:00
专场主席:
Fatima Karzai(Genitourinary Malignancies Branch, CCR, NCI, NIH)
Sophia Kamran(Massachusetts General Hospital and Harvard Medical School)
Abstract: LBA5000
讲者:Alberto Bossi, MD | Department of Radiation Oncology, Institute Gustave Roussy
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design。
新发、低体积、去势敏感性前列腺癌(mCSPC),经前列腺放射治疗患者:一项2x2设计的3期随机PEACE-1试验
Abstract:5001
讲者: Andrew J. Armstrong, MD | Duke Cancer Institute Center for Prostate & Urologic Cancers
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials
开发和验证基于人工智能的数字病理学生物标志物,以预测局部高危前列腺癌在多个III期NRG/RTOG试验中接受长期雄激素剥夺治疗的获益
Abstract:5002
讲者:Praful Ravi, MRCP, MBBChir | Dana-Farber Cancer Institute
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative
放疗结束后6个月内PSA最低值( n )≥0.1ng/mL对局限性前列腺癌患者预后的影响: 一项随机化ICECAP合作试验的个体患者数据(IPD)分析
Abstract:5003
讲者:David Olmos, MD, PhD | Hospital Universitario 12 de Octubre. Instituto de Investigación Sanitaria Hospital 12 de Octubre
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving firstline (1L) treatment stratified by BRCA status
按照BRCA状态分层,接受一线治疗的转移性去势抵抗性前列腺癌(mCRPC)患者中体细胞/种系同源重组修复(HRR)突变的存在和结局
Abstract:5004
讲者:Karim Fizazi, MD | Institut Gustave Roussy, University of Paris-Saclay
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations。
TALAPRO-2:talazoparib(TALA)+ 恩扎卢胺(ENZA)vs 安慰剂(PBO)+ ENZA作为一线治疗在转移性去势抵抗性前列腺癌(mCRPC)携带同源重组修复(HRR)基因改变的患者的Ⅲ期研究。
Abstract:5005
讲者:Shahneen Sandhu, MBBS, FRACP | Department of Medical Oncology, Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology, University of Melbourne
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)。
LuPARP研究:177Lu-PSMA-617和奥拉帕利治疗转移性去势抵抗性前列腺癌(mCRPC)患者的Ⅰ期试验
Abstract:5006
讲者:Lucia Nappi, MD, PhD, FRCPC | Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance。
对血浆miR371表达进行长期随访分析,以发现临床I期睾丸生殖细胞肿瘤患者的早期复发情况
Abstract:5007
讲者:Aditya Bagrodia, MD | University of California San Diego Health
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors
化疗初期与化疗后生殖细胞肿瘤的基因组和转录组图谱
Abstract:5008
讲者:Torgrim Tandstad, MD, PhD | St. Olav's University Hospital
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne
原发性腹膜后淋巴结清扫术治疗IIA-IIC ≤ 3cm阶段的精原细胞瘤患者:SWENOTECA (瑞典挪威睾丸癌小组)和科隆市的联合研究结果
膀胱癌/尿路上皮癌
6月6日 北京时间 00:30-03:30
专场主席:
Manojkumar Bupathi(Rocky Mountain Cancer Centers)
Neha Vapiwala(Abramson Cancer Center)
Abstract:4503
讲者: Enrique Grande, MD | MD Anderson Cancer Center
Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis。
阿替利珠单抗+铂类/吉西他滨 vs 安慰剂+ 铂类/吉西他滨一线治疗转移性尿路上皮癌患者的总生存期对比:IMvigor130 OS最终分析的更新数据
Abstract:4504
讲者:Arlene O. Siefker-Radtke, MD | Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study
Erdafitinib ( ERDA ) vs ERDA + cetrelimab ( ERDA + CET )治疗转移性尿路上皮癌( mUC)和成纤维细胞生长因子受体改变( FGFRa )的患者:Ⅱ期Norse研究最终结果
Abstract:4505
讲者:Shilpa Gupta, MD | Cleveland Clinic
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up。
EV-103剂量递增/队列A接近四年的长期研究结果:enfortumab vedotin+帕博利珠单抗一线治疗铂类不耐受的局部晚期或转移性尿路上皮癌患者的长期疗效
Abstract:LBA4507
讲者:Christian Pfister, MD, PhD | Rouen University Hospital
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial
一项比较剂量密集的甲氨蝶呤、长春新碱、多柔比星和顺铂( dd-MVAC)或吉西他滨和顺铂( GC )作为肌层浸润性膀胱癌(MIBC)围手术期化疗疗效的多中心随机Ⅲ期试验:GETUG / AFU V05 VESPER试验的5年总生存( OS )数据
Abstract:4508
讲者:Seth P. Lerner, MD | Baylor College of Medicine
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer
SWOG S1011:评估在根治性膀胱切除术时,对肌肉浸润性尿道癌进行标准淋巴结切除与扩展淋巴结切除取得临床获益的III期手术试验
Abstract:LBA4619(北京时间 6月5日 20:30)
讲者:Yohann Loriot, MD, PhD | Department of Cancer Medicine, Gustave Roussy Institute, INSERM 981, University Paris-Saclay
Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
THOR 3期研究:erdafitinib vs 化疗治疗具有选择性成纤维细胞生长因子受体突变的晚期或转移性尿路上皮癌患者的结果
肾癌
6月6日 北京时间 00:30-03:30
Abstract:LBA4500
讲者:Toni K. Choueiri, MD | Dana-Farber Cancer Institute, Harvard Medical School
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study
阿替利珠单抗+cabozantinib vs cabozantinib单药治疗进展期转移性肾细胞癌(RCC)的疗效和安全性:一项Ⅲ期、随机、开放标签的CONT-03研究的主要PFS分析
Abstract: LBA4501
讲者:Brian I. Rini, MD, FASCO | Vanderbilt-Ingram Cancer Center
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426。
帕博利珠单抗联合阿昔替尼 vs 舒尼替尼一线治疗晚期肾透明细胞癌:KEYNOTE-426研究的5年分析
Abstract:4502
讲者:Thomas E. Hutson, DO, FACP, PharmD | Texas Oncology
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
CLEAR研究预设的最终总生存期(OS)分析:仑伐替尼+帕博利珠单抗(L+P)vs 舒尼替尼(S)治疗晚期肾细胞癌(aRCC)患者的4年随访结果
Abstract:4506
讲者:Robert J. Motzer, MD | Memorial Sloan Kettering Cancer Center
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial
纳武利尤单抗+ipilimumab vs 安慰剂辅助治疗局限性肾癌术后高复发风险患者:来自Ⅲ期CheckMate 914(Part A)试验的亚组分析
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑:肿瘤资讯-CY